Placebo

A dummy treatment that looks like the real one but contains no active drug. Used in trials so researchers can tell how much of any improvement is due to the drug itself.

Also called: dummy pill, sugar pill, dummy drug, sham treatment, placebo group, dummy treatment, placebo-controlled

Related words randomised controlled trial double-blind clinical trial

Topics Research

Questions people ask

Is a pill camera (capsule endoscopy) safe if I might have Crohn's?

The main risk is the capsule getting stuck in a narrowed section of bowel. One NHS leaflet puts this at about 1 to 2 in 100 for bleeding checks, possibly 4 to 5 in 100 with Crohn's. Crohn's & Colitis UK says you may first be given a dissolvable dummy 'patency' capsule to check the way is clear. Biopsies cannot be taken with a capsule.

Sources

What is upadacitinib (Rinvoq) and how is it different from biologics?

Upadacitinib is a tablet that belongs to a group called JAK inhibitors. It blocks proteins inside cells that switch on the immune response, rather than being an antibody given by drip or injection. Trials found it worked better than placebo for moderate to severe Crohn's, and NICE recommends it after a biologic has failed or when anti-TNFs are unsuitable. Shingles was more common in people taking it.

Sources

Is vedolizumab still used for Crohn's?

NICE still recommends vedolizumab (Entyvio) after an anti-TNF has failed or is unsuitable, and a Cochrane review found it works better than placebo. However, the 2025 BSG guideline no longer routinely suggests it for moderate to severe Crohn's, because the effect seen in trials was small. The review of the guideline says it may still suit selected people, after discussion with the IBD team.

Sources

How can I take part in a Crohn's clinical trial?

The NHS suggests asking your doctor or a patient organisation about trials you may be eligible for. You can also search the NIHR's Be Part of Research website for UK studies and contact research teams directly. Registries such as ISRCTN and ClinicalTrials.gov list studies and their results. Crohn's & Colitis UK explains how new medicines are tested before they are licensed.

Sources

Where to read more

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

The Lancet Study May 2002 Patients and professionals

This trial asked whether people who improve after a first dose of infliximab should keep having it. Those given regular doses every 8 weeks were more likely to be in remission at 30 and 54 weeks, more likely to come off steroids, and stayed well for longer than those who stopped. Serious infections were no more common. It set the pattern of regular, ongoing infliximab treatment.

Topics Biologics and newer medicines Research

Jargon explained maintenance therapy remission placebo

Infliximab maintenance therapy for fistulizing Crohn's disease (ACCENT II)

New England Journal of Medicine Study Feb 2004 Patients and professionals

A trial in people with Crohn's fistulas (abnormal tunnels, often around the anus) who had responded to infliximab. Carrying on with infliximab every 8 weeks kept people well for much longer than switching to a dummy drug. At one year, 36% on infliximab had no draining fistulas, against 19% on placebo.

Topics Around the bottom (perianal) Biologics and newer medicines

Jargon explained fistula fistulizing disease placebo

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial

Gastroenterology Study Jan 2007 Patients and professionals

The main trial behind adalimumab (Humira and its biosimilars) for keeping Crohn's under control. People who improved on adalimumab were much more likely to still be in remission at about a year if they kept taking it (36-41%) than if switched to placebo (12%). Taking it weekly worked no better than every other week.

Topics Biologics and newer medicines

Jargon explained maintenance remission CDAI placebo

Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease (UNITI)

New England Journal of Medicine Study Nov 2016 Patients and professionals

The trials that led to ustekinumab (Stelara) being used for Crohn's. A first drip of ustekinumab helped more people improve than a dummy drip, and injections every 8 or 12 weeks afterwards kept about half of responders in remission at week 44, against about 36% on placebo. Side effects were similar between groups.

Topics Biologics and newer medicines

Jargon explained induction maintenance IL-12/23 placebo

Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease

Cochrane Systematic review Oct 2015 Patients and professionals

Cochrane pooled the trials of azathioprine and mercaptopurine for keeping Crohn's quiet. Low-quality evidence suggests azathioprine works better than placebo, but side effects such as pancreatitis, low white cell counts, sickness and infections limit its use. More good-quality trials are needed.

Topics Immunosuppressants Research

Jargon explained thiopurine low-quality evidence adverse event remission placebo systematic review

Risankizumab as maintenance therapy for moderately to severely active Crohn's disease (FORTIFY)

The Lancet Study May 2022 For professionals

The main international trial of risankizumab injections to keep Crohn's under control after a good response to drip treatment. More people who stayed on risankizumab remained in remission and had gut healing than those switched to placebo, and side effects were similar between groups.

Topics Biologics and newer medicines Research

Jargon explained IL-23 maintenance placebo endoscopic response

Tests and investigations

Crohn's & Colitis UK Guide Dec 2025 For patients

A detailed guide to the tests used to diagnose and monitor Crohn's and colitis: blood tests (full blood count, CRP, liver and kidney tests), poo tests including faecal calprotectin and FIT, endoscopies with tips on bowel prep, capsule endoscopy and the dummy patency capsule, and X-rays, CT, MRI and ultrasound. It explains what results can and cannot tell you, for example that calprotectin can be normal during a flare in the small bowel.

Topics Diagnosis and tests Monitoring

Jargon explained full blood count C-reactive protein faecal calprotectin faecal immunochemical test colonoscopy gastroscopy capsule endoscopy patency capsule biopsy bowel preparation

Upadacitinib Induction and Maintenance Therapy for Crohn's Disease (U-EXCEL, U-EXCEED, U-ENDURE)

New England Journal of Medicine Study May 2023 Patients and professionals

Three trials of upadacitinib (Rinvoq), a daily tablet rather than an injection or drip. It worked better than placebo both for settling active Crohn's over 12 weeks and for keeping it settled over a year. Some side effects, such as liver changes, low white cells and a few cases of bowel perforation, were seen more on the drug, so it needs monitoring.

Topics Medicines Immunosuppressants Research

Jargon explained JAK inhibitor small molecule induction maintenance herpes zoster endoscopic response

Vedolizumab as induction and maintenance therapy for Crohn's disease (GEMINI 2)

New England Journal of Medicine Study Aug 2013 Patients and professionals

The main trial of vedolizumab (Entyvio) in Crohn's. It helped more people reach remission than placebo by week 6, and people who responded and stayed on it were more likely to be in remission at one year. Side effects, including infections, were somewhat more common than on placebo in this trial.

Topics Biologics and newer medicines

Jargon explained integrin induction maintenance serious adverse event

Aminosalicylates for induction of remission or response in Crohn's disease

Cochrane Systematic review Jul 2016 Patients and professionals

Mesalazine-type drugs (aminosalicylates) are widely used for ulcerative colitis, but this review found little evidence that they work for active Crohn's. Low and high doses of mesalazine were not clearly better than placebo. Some trials comparing high-dose mesalazine with budesonide gave mixed results.

Topics Medicines

Jargon explained aminosalicylate 5-ASA mesalazine

Search everything for "placebo"